All the cases were provided retrospectively from the records of Firat University, Faculty of Medicine, Medical Oncology Department between 2009 and 2015. This study was approved by the Ethical Committee of Firat University. The patients included in the present study were diagnosed with PC and had received at least 6 cycles of TBR (75 mg, taxane mg/m2, every 21 days, intravenous infusion, together with 10 mg/day prednisone, peroral, continue) for mCRPC. All cases were evaluated every three cycles.